Ads
related to: first line treatment for travelers diarrhea antibiotics xifaxan injection
Search results
Results From The WOW.Com Content Network
Rifaximin, sold under the brand name Xifaxan among others, is a non-absorbable, broad-spectrum antibiotic mainly used to treat travelers' diarrhea. It is based on the rifamycin antibiotics family. Since its approval in Italy in 1987, it has been licensed in more than 30 countries for the treatment of a variety of gastrointestinal diseases like ...
Diarrhea due to viral agents is unaffected by antibiotic therapy, but is usually self-limited. [13] Protozoans such as Giardia lamblia, Cryptosporidium and Cyclospora cayetanensis can also cause diarrhea. Pathogens commonly implicated in travelers' diarrhea appear in the table in this section. [13] [16]
The rifamycin group includes the classic rifamycin drugs as well as the rifamycin derivatives rifampicin (or rifampin), rifabutin, rifapentine, rifalazil and rifaximin. Rifamycin, sold under the trade name Aemcolo, is approved in the United States for treatment of travelers' diarrhea in some circumstances. [1] [2] [3]
A U.S. appeals court on Thursday affirmed a decision for Bausch Health that barred rival drugmaker Alvogen from marketing a proposed generic version of Bausch's diarrhea treatment Xifaxan until 2029.
Wilderness-acquired diarrhea is a variety of traveler's diarrhea in which backpackers and other outdoor enthusiasts are affected. Potential sources are contaminated food or water, or "hand-to-mouth", directly from another person who is infected. [1] [2] Cases generally resolve spontaneously, with or without treatment, and the cause is typically ...
Rifaximin: Xifaxan: Traveler's diarrhea caused by E. coli: Carbacephem; Loracarbef: Lorabid: Discontinued: Prevents bacterial cell division by inhibiting cell wall synthesis. Carbapenems; Ertapenem: Invanz: Bactericidal for both Gram-positive and Gram-negative organisms and therefore useful for empiric broad-spectrum antibacterial coverage.